Diabetic Neuropathic PainPipeline Review, H2 2015
Summary
Global Markets Directs, Diabetic Neuropathic PainPipeline Review, H2 2015, provides an overview of the Diabetic Neuropathic Pains therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Diabetic Neuropathic Pain and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Diabetic Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Diabetic Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathic Pain Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Neuropathic Pain - Overview 10
Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis 11
Diabetic Neuropathic Pain - Therapeutics under Development by Companies 12
Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 15
Diabetic Neuropathic Pain - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Diabetic Neuropathic Pain - Products under Development by Companies 19
Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes 20
Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development 21
Astellas Pharma Inc. 21
AstraZeneca Plc 22
BioDelivery Sciences International, Inc. 23
Boehringer Ingelheim GmbH 24
Daiichi Sankyo Company, Limited 25
Dong-A Socio Group 26
Eli Lilly and Company 27
Glenmark Pharmaceuticals Ltd. 28
Hydra Biosciences, Inc. 29
Immune Pharmaceuticals Inc. 30
Laboratorios Del Dr. Esteve S.A. 31
Lohocla Research Corporation 32
Mertiva AB 33
Novaremed 34
Pharmaleads 35
RAPID Pharmaceuticals AG 36
Relmada Therapeutics, Inc. 37
Sphaera Pharma Pvt. Ltd. 38
Theravasc, Inc. 39
Diabetic Neuropathic Pain - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
(amitriptyline + ketamine hydrochloride) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
(diclofenac sodium + triclocarban) - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AS-1069562 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ASP-3662 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AZD-5213 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
clonidine hydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
duloxetine hydrochloride DR - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
E-52862 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
filgrastim - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
GERPOOI - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
GRC-17536 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
HC-030031 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Kindolor - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
mepivacaine hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
mirogabalin besylate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NG2-GAD - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NRD-135SE1 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PGN-305 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
PL-37 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
RAP-103 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
RAP-104 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecule to Agonize CB2 for Diabetic Neuropathic Pain - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
sodium nitrite SR - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Diabetic Neuropathic Pain - Recent Pipeline Updates 81
Diabetic Neuropathic Pain - Dormant Projects 90
Diabetic Neuropathic Pain - Discontinued Products 93
Diabetic Neuropathic Pain - Product Development Milestones 95
Featured News & Press Releases 95
Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37 95
Apr 22, 2015: Pharmaleads Announces the Inclusion of the First Patient in Phase IIa Study of Oral PL37 for Pain in Diabetic Neuropathy 96
Mar 30, 2015: BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 96
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 97
Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy 98
Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy 98
Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds 99
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 99
Feb 22, 2012: Shionogi And Lilly Japan Announce Approval Of Additional Indication For Cymbalta In Japan 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102
List of Tables
Number of Products under Development for Diabetic Neuropathic Pain, H2 2015 10
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Development by Companies, H2 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Investigation by Universities/Institutes, H2 2015 20
Diabetic Neuropathic Pain - Pipeline by Astellas Pharma Inc., H2 2015 21
Diabetic Neuropathic Pain - Pipeline by AstraZeneca Plc, H2 2015 22
Diabetic Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2015 23
Diabetic Neuropathic Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2015 24
Diabetic Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 25
Diabetic Neuropathic Pain - Pipeline by Dong-A Socio Group, H2 2015 26
Diabetic Neuropathic Pain - Pipeline by Eli Lilly and Company, H2 2015 27
Diabetic Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015 28
Diabetic Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H2 2015 29
Diabetic Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc., H2 2015 30
Diabetic Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2015 31
Diabetic Neuropathic Pain - Pipeline by Lohocla Research Corporation, H2 2015 32
Diabetic Neuropathic Pain - Pipeline by Mertiva AB, H2 2015 33
Diabetic Neuropathic Pain - Pipeline by Novaremed, H2 2015 34
Diabetic Neuropathic Pain - Pipeline by Pharmaleads , H2 2015 35
Diabetic Neuropathic Pain - Pipeline by RAPID Pharmaceuticals AG, H2 2015 36
Diabetic Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2015 37
Diabetic Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2015 38
Diabetic Neuropathic Pain - Pipeline by Theravasc, Inc., H2 2015 39
Assessment by Monotherapy Products, H2 2015 40
Assessment by Combination Products, H2 2015 41
Number of Products by Stage and Target, H2 2015 43
Number of Products by Stage and Mechanism of Action, H2 2015 45
Number of Products by Stage and Route of Administration, H2 2015 47
Number of Products by Stage and Molecule Type, H2 2015 49
Diabetic Neuropathic Pain Therapeutics - Recent Pipeline Updates, H2 2015 81
Diabetic Neuropathic Pain - Dormant Projects, H2 2015 90
Diabetic Neuropathic Pain - Dormant Projects (Contd..1), H2 2015 91
Diabetic Neuropathic Pain - Dormant Projects (Contd..2), H2 2015 92
Diabetic Neuropathic Pain - Discontinued Products, H2 2015 93
Diabetic Neuropathic Pain - Discontinued Products (Contd..1), H2 2015 94
List of Figures
Number of Products under Development for Diabetic Neuropathic Pain, H2 2015 10
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Products, H2 2015 18
Assessment by Monotherapy Products, H2 2015 40
Assessment by Combination Products, H2 2015 41
Number of Products by Top 10 Targets, H2 2015 42
Number of Products by Stage and Top 10 Targets, H2 2015 42
Number of Products by Top 10 Mechanism of Actions, H2 2015 44
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 44
Number of Products by Top 10 Routes of Administration, H2 2015 46
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 46
Number of Products by Top 10 Molecule Types, H2 2015 48
Number of Products by Stage and Top 10 Molecule Types, H2 2015 48
